Blog - Announcements

Vasomedical Named on the 2015 Technology Fast 500 List by Deloitte Four Years in a Row

PLAINVIEW, NY / ACCESSWIRE / November 16, 2015 / Vasomedical, Inc. (“Vasomedical”) (OTC BB: VASO) today announced that it has been named on the Deloitte’s Technology Fast 500(TM) list for the fourth consecutive year.

Deloitte’s Technology Fast 500 is a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America, based on percentage fiscal year revenue growth from 2011 to 2014.

Vasomedical’s Chief Executive Officer, Jun Ma, credits continued focus on the development of the Company’s existing operations as well as the diversification of its business portfolio for the growth the Company enjoyed during the three-year period. “We are honored to be included on this prestigious list of fast growing companies four years in a row,” stated Mr. Ma. “As we continue to execute our strategy based on the solid business foundation that we have built in the last several years, we expect continued growth of our Company.”

“Amid a fierce business climate, there seems to be no shortage of new and established companies that are unlocking a seemingly unlimited potential for growth and advancement through technology’s continued disruption and proliferation across industries,” said Sandra Shirai, principal, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “It is inspiring to witness the innovative ways that companies are incorporating emerging technologies for business gains, be it cognitive computing, or the Internet of Things. We congratulate all those ranked on this year’s Fast 500 and look forward to seeing their continued growth into 2016.”

About Vasomedical:

Vasomedical, Inc. is a diversified medical technology company with several distinct but related specialties: design, manufacture and sale of proprietary medical devices; professional sales services for diagnostic imaging products; and managed IT systems and services, including healthcare software solutions and network connectivity services.

Vasomedical operates through four wholly owned subsidiaries. Vaso Diagnostics, Inc. d.b.a. VasoHealthcare ( professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments in the USA. Vaso Technology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of GE Healthcare IT’s Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support; and NetWolves Network Services LLC (, a managed network services provider with an extensive, proprietary service platform to a broad base of customers. Vasomedical Solutions, Inc. ( and coordinates the operations of design, manufacture and sales of EECP(R) Therapy Systems and other proprietary medical equipment. Vasomedical Global Corp. ( the Company’s China-based subsidiaries, including Biox Instruments Co. Ltd. and Life Enhancement Technology Limited. It is also the minority shareholder of VSK Medical Limited, a marketing and sales company for ECP/EECP products in the international market. Additional information is available on the Company’s website at

Forward-Looking Statements:

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreements; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Link to Yahoo Finance: